What You Should Know
- Australian medical robotics and computational imaging startup Vexev raised $6M in new funding, bringing its total capital raised to date to $19M.
- The capital will support FDA 510(k) regulatory clearance, domestic manufacturing scale-up, and commercial launch in the United States for VxWave, its autonomous robotic tomographic ultrasound platform.
- VxWave combines precision robotics, artificial intelligence, and proprietary ultrasound signal processing to automate upper-limb vascular ultrasound acquisition without requiring a specialized sonographer or vascular surgeon to hold the probe.
- In a multi-center clinical study conducted with U.S. Renal Care (one of the largest dialysis providers in the U.S.), VxWave demonstrated a 94% scanning success rate when operated entirely by non-specialist clinical staff in routine dialysis workflows.
- The platform’s initial clinical application targets dialysis vascular access (arteriovenous fistulas and grafts), with planned expansion into peripheral artery disease (PAD) and broader cardiovascular diagnostics.
Vascular Imaging Reimagined
Vascular imaging has run into a serious staffing wall. While cardiovascular disease remains the leading cause of death worldwide, getting a reliable vascular ultrasound still depends almost entirely on having a highly trained sonographer in the room.
That bottleneck hits dialysis patients the hardest. Keeping an arteriovenous (AV) fistula or graft open is literally a lifeline for end-stage renal disease, but up to three out of four vascular access points end up failing or getting abandoned. Dialysis clinics rarely have dedicated sonographers on staff, meaning patients have to schedule separate hospital visits just to check blood flow. When those routine checks get delayed, minor narrowing turns into full-blown blockages, leading to emergency revisions and hospital stays that could have been prevented.
To fix that bottleneck, Australian medtech startup Vexev just raised $6M in new funding (bringing their total raised to $19 million) to push their autonomous robotic imaging system, VxWave, through FDA 510(k) clearance and into U.S. clinics.
Here is what the technology does and why it matters for outpatient care:
- Takes the Probe Out of Human Hands: Instead of relying on manual technique, the system uses a robotic arm to control probe movement, pressure, and contact. It automatically turns standard 2D ultrasound signals into full 3D volumetric maps of the vessel.
- Built for Non-Specialists: In clinical trials with U.S. Renal Care, regular clinic staff with no specialized ultrasound background hit a 94% scan completion rate, capturing diagnostic-quality flow data on their own.
- Consistent, Repeatable Data: Because a robot runs the scan, it removes human error and technique drift. Clinics get clear, objective numbers on vessel diameter, flow volume, and narrowing so they can spot a failing access point weeks before it shuts down.
- Broader Roadmap: While Vexev is starting with dialysis access, they plan to adapt the platform for peripheral artery disease (PAD), deep vein thrombosis (DVT), and general cardiovascular screenings down the line.
The new capital will go directly toward locking in FDA clearance, scaling up hardware manufacturing, and rolling out commercial pilots across U.S. dialysis and outpatient vascular centers.
